Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting
PEER
1 other identifier
observational
1,300
1 country
1
Brief Summary
LUNGevity Foundation, a non-profit lung cancer organization, wants to learn about living with lung cancer from the point of view of people with lung cancer and their family and friends who provide care. To do this, we have an online study designed to better understand how treatments people living with lung cancer receive impact their quality of life. Participants will complete surveys once a month for 12 months. What does participation involve?
- 1.Emailing the study team to learn more and get access to the study website.
- 2.Once a month for 12 months you will receive a survey by email.
- 3.Complete these surveys on a smartphone, tablet, or computer at your convenience and receive an e-gift card for your time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 15, 2020
CompletedFirst Submitted
Initial submission to the registry
April 12, 2023
CompletedFirst Posted
Study publicly available on registry
April 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedApril 28, 2023
April 1, 2023
4.3 years
April 12, 2023
April 26, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Explore guideline concordant care
Patient-reported treatments will be explored in relation to other clinical data provided (e.g., biomarker presence) and the National Comprehensive Cancer Network (NCCN) guidelines for those clinical characteristics at the time of treatment.
From baseline and assessed monthly up to end of study (up to approximately 12months)
Explore patient-reported functioning, symptoms, side effects and overall quality of life
Patterns based on disease staging and treatment class will be explored using the European Organisation for Research and Treatment of Cancer Quality of Life 30-item questionnaire (EORTC QLQ-C30), the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), and a side effect questionnaire to explore these patient-reported outcomes. Scores for the EORTC QLQ-C30 are transformed so that for each subscale the range is 0-100. For functioning subscales, higher scores indicate better functioning, and for symptoms higher scores indicate more symptom burden. Scores for the NSCLC-SAQ range from 0-20, with higher scores indicating more severe symptomology.
From baseline and assessed monthly up to end of study (up to approximately 12months)
Explore impacts of different classes of therapies
Test whether different classes of therapies (e.g., chemotherapy/ immunotherapy/ targeted therapy/ surgery/ radiation) impact patient experience (e.g., side effects, functioning). Both within and between patient experiences will be investigated. Results from Project PEER will be compared currently existing clinical trial data.
From baseline and assessed monthly up to end of study (up to approximately 12months)
Other Outcomes (1)
Impact of the pandemic on access to treatment
Baseline survey - Temporary COVID-19 module
Study Arms (2)
Patients
Individuals who have been diagnosed with lung cancer. Individuals with all stages of lung cancer and individuals who have reached no evidence of disease (NED).
Caregivers
Family and friends who provide care for someone who has been diagnosed with lung cancer
Interventions
There are no interventions in this study. All participants complete online surveys.
Eligibility Criteria
People who have been diagnosed with lung cancer and family and friends who care for someone with a lung cancer diagnosis. PEER is an international study, so participants can live anywhere as long as they meet the inclusion criteria.
You may qualify if:
- Adults with self-reported lung cancer diagnosis or caregiver of someone with a self-reported lung cancer diagnosis (patient has to be alive)
- Ability to read and answer questions in English
- Access and ability to use a computer or other internet-connected device
You may not qualify if:
- Younger than 18
- Healthcare providers and healthcare professionals who provide care to lung cancer patients except for those who are themselves a patient or a caregiver to a loved one.
- Not able to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LUNGevity Foundationlead
- Amgencollaborator
- AstraZenecacollaborator
- Blueprint Medicines Corporationcollaborator
- Boehringer Ingelheimcollaborator
- Bristol-Myers Squibbcollaborator
- Eli Lilly and Companycollaborator
- G1 Therapeutics, Inc.collaborator
- Genentech, Inc.collaborator
- Janssen, LPcollaborator
- Jazz Pharmaceuticalscollaborator
- Merck Sharp & Dohme LLCcollaborator
- Novartiscollaborator
- Takedacollaborator
Study Sites (1)
LUNGevity Foundation
Bethesda, Maryland, 20814, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Upal Basu Roy, PhD, MPH
LUNGevity Foundation
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 12, 2023
First Posted
April 24, 2023
Study Start
August 15, 2020
Primary Completion
December 1, 2024
Study Completion
December 1, 2025
Last Updated
April 28, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share